目的 探究千柏鼻炎胶囊联合枸地氯雷他定片治疗变应性鼻炎的临床疗效。方法 选取2016年9月—2017年10月武汉市普仁医院收治的122例变应性鼻炎患者作为研究对象，所有患者随机分为对照组和治疗组，每组各61例。对照组口服枸地氯雷他定片，8.8 mg/次，1次/d。治疗组在对照组基础上口服千柏鼻炎胶囊，1 g/次，3次/d。两组患者均治疗12 d。观察两组的临床疗效，比较两组的临床症状评分、血清指标和复发率。结果 治疗后，对照组和治疗组的总有效率分别为83.61%、95.08%，两组比较差异有统计学意义（P<0.05）。治疗后，两组喷嚏、擤鼻、鼻塞、鼻痒评分及其总分均显著降低，同组治疗前后比较差异有统计学意义（P<0.05）；且治疗后治疗组临床症状评分显著低于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组特异性免疫球蛋白E（sIgE）、总免疫球蛋白E（T-IgE）、白三烯B4（LTB4）、嗜酸性粒细胞（EOS）水平均显著降低，同组治疗前后比较差异具有统计学意义（P<0.05）；且治疗后治疗组血清指标水平显著低于对照组，两组比较差异有统计学意义（P<0.05）。对照组和治疗组随访3、6个月，复发率分别为27.87%、47.54%，9.84%、29.51%，两组复发率比较差异具有统计学意义（P<0.05）。结论 千柏鼻炎胶囊联合枸地氯雷他定片治疗变应性鼻炎具有较好的临床疗效，能改善临床症状，降低炎症反应，降低复发率，具有一定的临床推广应用价值。

Objective To explore the clinical effect of Qianbai Biyan Capsules combined with Desloratadine Citrate Disodium Tablets in treatment of allergic rhinitis. Methods Patients (122 cases) with allergic rhinitis in Wuhan Puren Hospital from September 2016 to October 2017 were randomly divided into control and treatment groups, and each group had 61 cases. Patients in the control group were po administered with Desloratadine Citrate Disodium Tablets, 8.8 mg/time, once daily. Patients in the treatment group were po administered with Qianbai Biyan Capsules on the basis of the control group, 1 g/time, three times daily. Patients in two groups were treated for 12 d. After treatment, the clinical efficacies were evaluated, and clinical symptom scores, related serum indexes, and recurrence rates in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 83.61% and 95.08%, respectively, and there was difference between two groups (P<0.05). After treatment, symptom scores and total scores of sneezing, nose blowing, nasal obstruction and itching in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the clinical symptom scores in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, the levels of sIgE, T-IgE, LTB4, and EOS in two groups were significantly decreased, and the difference was statistically significant in the same group (P <0.05). And the related serum indexes levels in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). Follow-up for 3 and 6 months, the recurrence rates in the control and treatment groups were 27.87% and 9.84%, and 47.54% and 29.51%, respectively, and there was difference between two groups (P<0.05). Conclusion Qianbai Biyan Capsules combined with Desloratadine Citrate Disodium Tablets has clinical curative effect in treatment of allergic rhinitis, can improve clinical symptoms, reduce inflammatory response, and reduce recurrence rate, which has a certain clinical application value.